Phase I Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Bortezomib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 09 Dec 2013 Status changed from recruiting to completed.
- 14 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History